Tag: MEDESIS
Medesis Pharma: strategic point
(Boursier.com) — Medesis Pharma, a pharmaceutical biotechnology company developing drug candidates with its proprietary oral active delivery technology, Aonys, shares an information note on the three drug candidates in development…
Medesis pharma: Medesis biotech accelerates to treat irradiated people after a nuclear accident
(BFM Bourse) – The Montpellier biotech, which is developing, with the Atomic Energy Commission (LRT-CEA), three drugs specifically intended for the treatment of large populations contaminated or irradiated after a…
Medesis wants to accelerate in anti-nuclear products, message received 5 out of 5 on the stock market
The biotech, which has developed a technology for administering active ingredients by microemulsion, recalls on Tuesday that three of its products currently in development are effective in the treatment of…
Medesis wants to accelerate in the antinuclear, message received on the Stock Exchange
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? To sell ? What course objective? Our experts engage…
MEDESIS PHARMA CONFIRMS ITS ELIGIBILITY FOR PEA-PME – 2022-01-14 at 18:00
Montpellier, January 14, 2022 – 6:00 p.m. – Medesis Pharma, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for the administration of active ingredients in nano…